Aliases & Classifications for Vesiculobullous Skin Disease

MalaCards integrated aliases for Vesiculobullous Skin Disease:

Name: Vesiculobullous Skin Disease 12 15
Skin Diseases, Vesiculobullous 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2731
MeSH 44 D012872
UMLS 73 C0037275

Summaries for Vesiculobullous Skin Disease

MalaCards based summary : Vesiculobullous Skin Disease, also known as skin diseases, vesiculobullous, is related to skin disease and epidermolysis bullosa simplex with pyloric atresia, and has symptoms including exanthema and pruritus. An important gene associated with Vesiculobullous Skin Disease is COL7A1 (Collagen Type VII Alpha 1 Chain), and among its related pathways/superpathways are Integrin Pathway and Phospholipase-C Pathway. The drugs Tetracycline and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are craniofacial and digestive/alimentary

Related Diseases for Vesiculobullous Skin Disease

Diseases related to Vesiculobullous Skin Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 skin disease 23.1 CD79A COL17A1 COL7A1 DST EXPH5 ITGB4
2 epidermolysis bullosa simplex with pyloric atresia 10.6 ITGB4 PLEC
3 epidermolysis bullosa simplex, autosomal recessive 1 10.5 KRT14 KRT5
4 pemphigoid gestationis 10.5 COL17A1 DST
5 benign breast adenomyoepithelioma 10.5 KRT14 KRT5
6 herpes gestationis 10.5 COL17A1 DST
7 large cell acanthoma 10.5 KRT14 KRT5
8 apocrine sweat gland neoplasm 10.5 KRT14 KRT5
9 epidermolysis bullosa simplex, generalized 10.4 KRT14 KRT5
10 breast squamous cell carcinoma 10.4 KRT14 KRT5
11 odontoma 10.4 KRT14 KRT5
12 breast adenomyoepithelioma 10.4 KRT14 KRT5
13 breast myoepithelial neoplasm 10.4 KRT14 KRT5
14 cervical clear cell adenocarcinoma 10.4 KRT14 KRT5
15 epidermolysis bullosa simplex, dowling-meara type 10.3 KRT14 KRT5
16 lipoadenoma 10.3 KRT14 KRT5
17 epidermolysis bullosa dystrophica 10.3 COL7A1 DST
18 lipid-rich carcinoma 10.3 KRT14 KRT5
19 intraneural perineurioma 10.3 KRT14 KRT5
20 neurotic excoriation 10.3 COL17A1 COL7A1 DST
21 white sponge nevus 1 10.3 KRT14 PLEC
22 pre-malignant neoplasm 10.2 KRT14 KRT5
23 lichen planopilaris 10.2 COL17A1 KRT14 KRT5
24 epidermolysis bullosa simplex with muscular dystrophy 10.2 COL17A1 DST PLEC
25 ecthyma 10.2 COL17A1 DST
26 ichthyosis bullosa of siemens 10.1 KRT14 KRT5 PLEC
27 kindler syndrome 10.1 COL7A1 DST ITGB4
28 lichen planus pemphigoides 10.1 COL17A1 DST ITGB4
29 epidermolysis bullosa simplex, localized 10.1 ITGB4 KRT14 KRT5
30 in situ carcinoma 10.1 ITGB4 KRT14 KRT5
31 aplasia cutis congenita 10.1 COL7A1 ITGA6 ITGB4
32 sweat gland cancer 10.0 KRT14 KRT5
33 epidermolysis bullosa with pyloric atresia 10.0 ITGA6 ITGB4 PLEC
34 maternal uniparental disomy of chromosome 1 10.0 LAMA3 LAMB3 LAMC2
35 epidermolysis bullosa, junctional, herlitz type 10.0 LAMA3 LAMB3 LAMC2
36 paraneoplastic pemphigus 9.9 COL17A1 DST
37 epidermolysis bullosa simplex with mottled pigmentation 9.9 EXPH5 KRT14 KRT5
38 hymenolepiasis 9.8 CD79A KRT5
39 skin benign neoplasm 9.7 KRT14 KRT5
40 lichen disease 9.6 CD79A COL17A1 DST
41 subcorneal pustular dermatosis 9.6 CD79A COL17A1 DST
42 hypersensitivity reaction disease 9.5 CD79A COL17A1 DST
43 pemphigus 9.5 CD79A COL17A1 DST
44 ocular cicatricial pemphigoid 9.4 CD79A ITGA6 ITGB4
45 pyloric atresia 9.3 COL17A1 ITGA6 ITGB4 LAMC2 PLEC
46 epidermolysis bullosa junctionalis with pyloric atresia 9.2 COL17A1 DST ITGA6 ITGB4 PLEC
47 linear iga disease 9.2 CD79A COL17A1 DST ITGB4
48 epidermolysis bullosa simplex 8.9 COL17A1 DST ITGB4 KRT14 KRT5 PLEC
49 bullous skin disease 8.9 CD79A COL17A1 DST LAMA3
50 autoimmune disease of skin and connective tissue 8.5 CD79A COL17A1 DST LAMA3 PLEC

Graphical network of the top 20 diseases related to Vesiculobullous Skin Disease:



Diseases related to Vesiculobullous Skin Disease

Symptoms & Phenotypes for Vesiculobullous Skin Disease

UMLS symptoms related to Vesiculobullous Skin Disease:


exanthema, pruritus

MGI Mouse Phenotypes related to Vesiculobullous Skin Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.97 COL7A1 ITGA6 ITGB4 KRT14 KRT5 LAMA3
2 digestive/alimentary MP:0005381 9.92 LAMB3 LAMC2 COL7A1 ITGA6 ITGB4 KRT14
3 growth/size/body region MP:0005378 9.91 COL7A1 ITGA6 ITGB4 KRT14 KRT5 LAMA3
4 integument MP:0010771 9.81 COL7A1 ITGA6 ITGB4 KRT14 KRT5 LAMA3
5 mortality/aging MP:0010768 9.61 COL7A1 ITGA6 ITGB4 KRT14 KRT5 LAMA3
6 respiratory system MP:0005388 9.1 ITGA6 ITGB4 KRT14 LAMA3 LAMB3 LAMC2

Drugs & Therapeutics for Vesiculobullous Skin Disease

Drugs for Vesiculobullous Skin Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 53-03-2 5865
3
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 25122-46-7, 25122-41-2 32798 5311051
4
Ephedrine Approved Phase 4 299-42-3 9294
5
Pseudoephedrine Approved Phase 4 90-82-4 7028
6
Omalizumab Approved, Investigational Phase 4 242138-07-4
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
9
Dapsone Approved, Investigational Phase 4,Phase 2,Phase 1 80-08-0 2955
10
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
11
Ticagrelor Approved Phase 4 274693-27-5 9871419
12
Ticlopidine Approved Phase 4 55142-85-3 5472
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
20 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
21 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones Phase 4,Phase 3,Phase 2,Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Respiratory System Agents Phase 4
26 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
31 Nasal Decongestants Phase 4
32 Ophthalmic Solutions Phase 4
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
34 Tetrahydrozoline Phase 4
35 Vasoconstrictor Agents Phase 4
36 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1
37 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Allergic Agents Phase 4,Phase 3
43 Anti-Asthmatic Agents Phase 4
44 Immunoglobulin E Phase 4
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
46 Analgesics, Opioid Phase 4
47 Central Nervous System Depressants Phase 4
48 Narcotics Phase 4
49 Antifungal Agents Phase 4,Phase 3,Phase 2,Early Phase 1
50 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa Unknown status NCT00336154 Phase 4 tetracyclin
2 Evaluation of Three Types of Dressings After Hip Surgery Completed NCT01469871 Phase 4
3 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
4 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
5 Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa Completed NCT00231517 Phase 4 topical opiod;morphine sulphate in intrasite gel
6 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
7 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
8 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
9 Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction Recruiting NCT02931045 Phase 4 Ticagrelor;Clopidogrel
10 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
11 Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis Terminated NCT01115244 Phase 4 Dapsone gel, 5%
12 A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa Terminated NCT01619670 Phase 4
13 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
14 Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Unknown status NCT01974518 Phase 3 Rituximab and Cyclophosphamide IV
15 Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin Unknown status NCT01340235 Phase 3 Oral erythromycin
16 Prevention Trial Assessing Paper-Tape in Endurance Distances (PreTAPED) Completed NCT01120808 Phase 3
17 Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris Completed NCT02828163 Phase 3 Triamcinolone Acetonide
18 Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris Completed NCT01920477 Phase 3
19 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
20 Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Completed NCT01299857 Phase 3 Rituximab
21 Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus Completed NCT00784589 Phase 3 General Corticotherapy;Rituximab
22 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) Completed NCT00683930 Phase 3 Mycophenolate Mofetil 2 g/Day;Mycophenolate Mofetil (MMF) 3 g/Day;Placebo
23 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
24 Effect of Anti CD20 in Pemphigus Desease Completed NCT00213512 Phase 2, Phase 3 Mabthera
25 European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Completed NCT00127764 Phase 2, Phase 3 dexamethasone (50mg 1dd6, 3 consecutive days/month)
26 Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs Completed NCT01065116 Phase 3 AL Blister-packs with Instruction leaflets;AL unit dose age specific pre-packs
27 ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa Completed NCT02384460 Phase 3 SD-101-6.0 cream;SD-101-0.0 cream
28 Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer Completed NCT01825642 Phase 2, Phase 3
29 Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
30 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Completed NCT00346450 Phase 3
31 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Recruiting NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
32 Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa Recruiting NCT03068780 Phase 3 Oleogel-S10;Placebo
33 A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane Recruiting NCT02286427 Phase 3
34 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Active, not recruiting NCT02383589 Phase 3 Mycophenolate Mofetil Placebo;Mycophenolate Mofetil;Rituximab;Rituximab Placebo
35 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
36 Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Not yet recruiting NCT03453632 Phase 2, Phase 3 Botulinic toxin;Placebo
37 Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
38 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
39 A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing Terminated NCT01749306 Phase 3
40 Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) Terminated NCT00587223 Phase 3
41 Subconjunctival Bevacizumab Effect on Bleb Vascularity Unknown status NCT00854529 Phase 2 Bevacizumab
42 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
43 Diacerin for the Treatment of Epidermolysis Bullosa Simplex Unknown status NCT02470689 Phase 2 Diacerin cream
44 Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Unknown status NCT00936533 Phase 2 Dysport® (Botulinumtoxin A (Btx A));Placebo
45 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Completed NCT02226146 Phase 2
46 Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
47 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
48 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Completed NCT00656656 Phase 2 Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
49 Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone Completed NCT00626678 Phase 2 Azathioprine;Prednisone;Placebo
50 Use of KC706 for the Treatment of Pemphigus Vulgaris Completed NCT00606749 Phase 2 KC706

Search NIH Clinical Center for Vesiculobullous Skin Disease

Cochrane evidence based reviews: skin diseases, vesiculobullous

Genetic Tests for Vesiculobullous Skin Disease

Anatomical Context for Vesiculobullous Skin Disease

MalaCards organs/tissues related to Vesiculobullous Skin Disease:

41
Skin, Eye, T Cells, Prostate, Neutrophil, Endothelial, Salivary Gland

Publications for Vesiculobullous Skin Disease

Articles related to Vesiculobullous Skin Disease:

# Title Authors Year
1
Vesiculobullous skin disease with prominent immunologic feature. ( 3312674 )
1987

Variations for Vesiculobullous Skin Disease

Expression for Vesiculobullous Skin Disease

Search GEO for disease gene expression data for Vesiculobullous Skin Disease.

Pathways for Vesiculobullous Skin Disease

Pathways related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 COL17A1 COL7A1 ITGA6 ITGB4 LAMA3 LAMB3
2
Show member pathways
12.81 CD79A COL17A1 COL7A1 ITGA6 ITGB4 LAMA3
3
Show member pathways
12.78 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
4
Show member pathways
12.71 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5 12.62 ITGA6 LAMA3 LAMB3 LAMC2
6
Show member pathways
12.62 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
7
Show member pathways
12.38 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
8
Show member pathways
12.33 COL17A1 COL7A1 DST ITGA6 ITGB4 LAMA3
9
Show member pathways
12.15 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
10
Show member pathways
12.07 ITGA6 LAMA3 LAMB3 LAMC2
11
Show member pathways
11.94 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
12
Show member pathways
11.93 COL17A1 COL7A1 DST ITGA6 ITGB4 LAMA3
13
Show member pathways
11.91 ITGA6 ITGB4 LAMA3
14 11.84 ITGA6 ITGB4 PLEC
15
Show member pathways
11.79 DST KRT14 KRT5 PLEC
16 11.73 LAMA3 LAMB3 LAMC2
17 11.7 ITGA6 LAMA3 LAMB3 LAMC2
18 11.5 LAMA3 LAMB3 LAMC2
19
Show member pathways
11.48 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
20 11.21 ITGA6 ITGB4
21 11.14 ITGB4 LAMA3
22 11.14 COL17A1 ITGA6 ITGB4

GO Terms for Vesiculobullous Skin Disease

Cellular components related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.5 DST KRT14 KRT5
2 basement membrane GO:0005604 9.5 COL17A1 COL7A1 DST ITGA6 LAMA3 LAMB3
3 basal plasma membrane GO:0009925 9.37 DST ITGA6
4 integrin complex GO:0008305 9.26 ITGA6 ITGB4
5 laminin-5 complex GO:0005610 9.16 LAMA3 LAMB3
6 hemidesmosome GO:0030056 9.02 COL17A1 DST ITGA6 ITGB4 PLEC

Biological processes related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.8 COL7A1 DST ITGA6 ITGB4 LAMA3 LAMB3
2 cell-matrix adhesion GO:0007160 9.65 COL17A1 ITGA6 ITGB4
3 integrin-mediated signaling pathway GO:0007229 9.63 DST ITGA6 ITGB4
4 extracellular matrix organization GO:0030198 9.63 COL7A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5 extracellular matrix disassembly GO:0022617 9.58 LAMA3 LAMB3 LAMC2
6 digestive tract development GO:0048565 9.54 ITGA6 ITGB4
7 brown fat cell differentiation GO:0050873 9.52 ITGA6 LAMB3
8 cell motility GO:0048870 9.51 DST ITGB4
9 endodermal cell differentiation GO:0035987 9.5 COL7A1 LAMA3 LAMB3
10 epidermis development GO:0008544 9.5 COL17A1 COL7A1 KRT14 KRT5 LAMA3 LAMB3
11 renal system development GO:0072001 9.49 ITGA6 ITGB4
12 amelogenesis GO:0097186 9.43 ITGA6 ITGB4
13 nail development GO:0035878 9.37 ITGA6 ITGB4
14 hemidesmosome assembly GO:0031581 9.28 COL17A1 ITGA6 ITGB4 KRT14 KRT5 LAMA3

Molecular functions related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor I binding GO:0031994 8.96 ITGA6 ITGB4
2 neuregulin binding GO:0038132 8.62 ITGA6 ITGB4

Sources for Vesiculobullous Skin Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....